Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma

Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone(CHOP) is an eicient treatment of non-Hodgkin's lymphoma(NHL). This study aimed to assess the eicacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab(R-CHOP) by examining the stem cell mobilization in NHL patients. Factors afecting the collection of CD34+ cells were also explored.Methods: Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were inancially eligible received R-CHOP for autologous peripheral blood stem cell(APBSC) mobilization; the remaining 25 patients received CHOP.Results: The median CD34+ cell yield was 7.01 × 106 cells/kg body weight(range 1.49–28.39 × 106 cells/kg body weight), with only two patients failing to meet the target CD34+ cell harvest of ber of apheresis procedures per patient was 1(range 1–3). The≥2.0 APBS× 106 cells/kg body weight. The median numC mobilization yield of the CHOP group appeared to be higher than that of the R-CHOP group(P response(CR) rate in = 0.005), whereas the success rate was similar between groups. R-CHOP elevated the completeB cell lymphoma patients as compared with CHOP(P = 0.01). No signiicant diferences in toxicity or engraftment were observed between the two groups.Conclusion: The present study demonstrated that dose-adjusted CHOP chemotherapy efectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for patients with B-cell lymphoma.

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin＇s lymphoma

Objective： This study was designed to determine the safety, pharmacokinetics and biologic effects of a humanmouse chimeric anti-CD20 monoclonal antibody （SCT400） in Chinese padents with CD20-positive B-cell non- Hodgkin＇s lymphoma （CD20 B-cell NHL）. SCT400 has an identical amino acid sequence as rituximab, with the exception of one amino acid in the CH1 domain of the heavy chain, which is common in Asians. Methods： Fifteen patients with CD20＋ B-cell NHL received dose-escalating SCT400 infusions （250 mg/m2： n=3; 375 mg/m2： n=9; 500 mg/m2： n=3） once weekly for 4 consecutive weeks with a 24-week follow-up period. The data of all patients were collected for pharmacoklnetics and pharmacodynamics analyses. Results： No dose-limiting toxicities were observed. Most drug-related adverse events were grade 1 or 2. Two patients had grade 3 or 4 ncutropenia. Under premedication, the drug-related infusion reaction was mild. A rapid, profound and durable depletion of circulating B cells was observed in all dose groups without significant effects on T cell count, natural killer （NK） cell count or immunoglobulin levels. No patient developed anti- SCT400 antibodies during the course of the study. SCT400 serum half-life （Tin）, maximum concentration （Cmax and area under the curve （AUC） generally increased between the first and fourth infusions （P〈0.05）. At the 375 mg/m2 dose, the T1/2 was 122.5±46.7 h vs. 197.0,75.0 11, respectively, and the Cmax was 200.6±20.2 pg/mL vs. 339.1±71.0 ng/mL, respectively. From 250 mg/m2 to 500 mg/m2, the Cmax and AUC increased significantly in a dose-dependent manner （P〈0.05）. Patients with a high tumor burden had markedly lower serum SCT400 concenmations compared with those without or with a low tumor burden. Of the 9 assessable patients, 1 achieved complete response and 2 achieved partial responses. Conclusions; SCT400 is well-tolerated and has encouraging preliminary efficacy in Chinese patients with CD20＋ B-cell NHL.

Constructing nanocomposites with robust covalent connection between nanoparticles and polymer for high discharged energy density and excellent tensile properties

High discharged energy density and excellent flexible properties in dielectric materials are significantly sought to meet the rapid advancements in the electronics industry. In this study, covalent bonds are constructed between poly(vinylidene fluoride-chlorotrifluoroethylene), which contains olefinic bonds, and thiol-modified BaTiO_(3) at the interface before the nanocomposite films are fabricated. The presence of the covalent bonds is proved to promote the dispersibility of the modified BaTiO_(3) and enhance the interfacial adhesion between the modified BaTiO_(3) and the polymer, followed by a remarkably positive effect in suppressing the dielectric loss(tanδ) and increasing the breakdown strength(Eb) of the nanocomposite films. In addition, the cross-linking treatment in the preparation process is found to be favourable for improving the mechanical properties of the nanocomposite films, which benefits the enhancement of Eb. Furthermore, at 400% elongation, the stretched nanocomposite film doped with 5 vol% modified BaTiO_(3) exhibits an Eb15.6% greater than that of the unstretched film, and the discharged energy density reaches 11.4 J/cm^(3) with a high discharge energy efficiency of 84.5%. This study provides a novel strategy for preparing flexible nanocomposites with powerful interfacial adhesion at high filler content to achieve high discharged energy density.

A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor(PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia

Objective： The recommended dose of prophylactic pegylated recombinant human granulocyte-colony stimulating factor（PEG rhG-CSF） is 100 μg/kg once per cycle for patients receiving intense-dose chemotherapy.However, few data are available on the proper dose for patients receiving less-intense chemotherapy. The aim of this phase I study is to explore the proper dose and administration schedule of PEG rhG-CSF for patients receiving standard-dose chemotherapy.Methods：Eligible patients received 3-cycle chemotherapy every 3 weeks.No PEG rhG-CSF was given in the first cycle.Patients experienced grade 3 or 4 neutropenia would then enter the cycle 2 and 3.In cycle 2,patients received a single subcutaneous injection of prophylactic PEG rhG-CSF on d 3,and received half-dose subcutaneous injection in cycle 3 on d 3 and d 5,respectively.Escalating doses（30,60,100 and 200μg/kg）of PEG rhG-CSF were investigated.Results：A total of 26 patients were enrolled and received chemotherapy,in which 24 and 18 patients entered cycle 2 and cycle 3 treatment,respectively.In cycle 2,the incidence of grade 3 or 4 neutropenia for patients receiving single-dose PEG rhG-CSF of 30,60,100 and 200 μg/kg was 66.67%,33.33%,22.22% and 0,respectively,with a median duration less than 1（0–2）d.No grade 3 or higher neutropenia was noted in cycle 3 in all dose cohorts.Conclusions：The pharmacokinetic and pharmacodynamic profiles of PEG rhG-CSF used in cancer patients were similar to those reported,as well as the safety.Double half dose administration model showed better efficacy result than a single dose model in terms of grade 3 neutropenia and above.The single dose of 60 μg/kg,100 μg/kg and double half dose of 30 μg/kg were recommended to the phase Ⅱ study,hoping to find a preferable method for neutropenia treatment.

Pathobiology of ovarian carcinomas

Ovarian tumors comprise a heterogeneous group of lesions, displaying distinct tumor pathology and oncogenic potentiel. These tumors are subdivided into three main categories: epithelial, germ cell, and sex-cord stromal tumors. We report herein the newly described molecular abnormalities in epithelial ovarian cancers(carcinomas). Immunohistochemistry and molecular testing help pathologists to decipher the significant heterogeneity of this disease. Our better understanding of the molecular basis of ovarian carcinomas represents the first step in the development of targeted therapies in the near future.

植物病原真菌抑制杂草的活性筛选及菌株CY-H的活性代谢产物

【目的】分离并鉴定具有较好除草活性的植物病原真菌菌株,进一步分离活性化合物,为开发新型生物源除草剂奠定一定的基础。【方法】采用固体培养基接种法分离纯化植物病原真菌,通过形态学特征观察和5.8S rDNA测序鉴定目标菌株;在活性筛选追踪下,对活性组分进行追踪分离及纯化,经波谱分析确定活性单体化合物结构;采用培养皿生物分析法测定活性单体化合物的除草活性及对常见作物的安全性。【结果】茶叶致病菌CY-H具有较好的除草活性,其发酵液对稗草和反枝苋根的抑制率分别为94.6%和77.3%。CY-H被鉴定为间座壳属菌(Diaporthe sp.)。从CY-H菌中分离得到单体化合物CY1被鉴定为cytosporaphenones C。在供试浓度为100μg/mL时,CY1具有较好的抑制反枝苋根的活性,抑制率为57.1%,且其对小麦和油菜的安全性较好,抑制率均在20%左右。【结论】茶叶致病菌CY-H具有开发成微生物源除草剂的潜力。

Determining the optimum range of soil Olsen P for high P use efficiency, crop yield, and soil fertility in three typical cropland soils

Soil Olsen P level has a major influence on crop yield,efficient P utilization,and soil fertility.In this study,the optimum Olsen P range was determined from long-term(1990–2012)field experiments in three typical soil types of China under single cropping of maize or double cropping of maize and wheat.The critical soil Olsen P value for crop yield was evaluated using three different models,and the relationships among P use efficiency(PUE),Olsen P,and total P were analyzed.The agronomic critical soil Olsen P values obtained from the three models for the neutral soil of Gongzhuling and the calcareous soil of Zhengzhou were similar;however,the values from the linear-linear and linear-plateau models for both maize and wheat were substantially lower than those from the Mitscherlich model for the acidic soil of Qiyang.The PUE response change rates(linear equation slopes)under different soil Olsen P levels were small,indicating slight or no changes in the PUE as the soil Olsen P increased in all three soils.A comparison of the Olsen P levels that achieved the maximal PUE with the agronomic critical values derived from the three models indicated that the linear-plateau model exhibited the best performance.The regression equation coefficients of Olsen P response to total P decreased as follows:Zhengzhou(73 mg g-1)>Qiyang(65 mg g-1)>Gongzhuling(55 mg g-1).The Olsen P level increased as the total P increased,which may result in a decrease in PUE.To achieve a relatively high crop yield,PUE,and soil fertility,the optimum Olsen P range should be 13–40,10–40,and 29–40 mg kg-1 at Gongzhuling,Zhengzhou,and Qiyang,respectively.

Preparation of slightly crosslinked monodisperse poly(maleic anhydride-cyclohexyl vinyl ether-divinylbenzene)functional microspheres with anhydride groups via precipitation polymerization

Slightly crosslinked monodisperse poly（maleic anhydride-cyclohexyl vinyl ether-divinylbenzene） （MA-CHVE-DVB） microspheres were prepared via precipitation polymerization while using 2,2- azobisisobutyronitrile as an initiator in a mixture of methyl ethyl ketone and n-heptane without any stabilizer. The number-average diameter of the resultant poly（MA-CHVE-DVB） microspheres ranged from 0.478 to 1.386 μm with a polydispersity index of 1.00 to 1.02 that depended on the feed ratios of the MA/CHVE/DVB monomers. The introduction of one electron donor monomer cyclohexyl vinyl ether strongly affected the yield, size, and morphology of these slightly crosslinked microspheres. Quinoline- type chelating resins were obtained after combining the poly（MA-CHVE-DVB） with 8-hydroxyquinoline; the adsorption properties of these materials were measured through their ability to remove Cu^2＋ ions from water. The poly（MA-CHVE-DVB） microspheres with low degrees of crosslinking provided more effective functional groups and therefore better ion removal capabilities. These slightly crosslinked microspheres may have applications in water treatment as well as in sensing and drug delivery.

A cell retrievable strategy for harvesting extracellular matrix as active biointerface

Extracellular matrix(ECM) provides a variety of physical and chemical cues for cells. Here, a very simple and smart method is developed to glue living cells away for harvesting their ECMs. The obtained ECM coatings show less cell fragment residues comparing with those obtained by the traditional cell lysis. The glued cell sheets can even be re-cultured and reused after transferring to new environment. This moderate way well maintains the activity of the ECM proteins, which can promote cell adhesion and growth.Strikingly, the ECM coatings acquired from different functional cells can guide stem cell differentiation,which is attributed to the natural physical and biochemical cues on ECM coatings. Consequently, this method provides a substantial progress for preparing natural ECM coatings and shows promising potential in regenerative medicine and other related fields of biomedical engineering.

Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma:Results of a prospective randomized study

Background:Chemotherapy plus granulocyte colony-stimulating factor (GCSF) regimen is one of the available approaches to mobilize peripheral blood progenitor cells (PBPCs).It causes thrombocytopenia and delays leukapheresis.This study aimed to evaluate the role of recombinant human thrombopoietin (rhTPO) before mobilization chemotherapy in facilitating leukapheresis in patients with lymphoma.Methods:In this randomized open-label phase 2 trial, patients were randomly assigned in a 1:2 ratio to receive mobilization with rhTPO plus GCSF in combination with chemotherapy (the rhTPO plus GCSF arm) or GCSF alone in combination with chemotherapy (the GCSF alone arm).The recovery of neutrophils and platelets and the amount of platelet transfusion were monitored.Results:Thirty patients were enrolled in this study between March 2016 and August 2018. Patients in the rhTPO plus GCSF arm (n = 10) had similar platelet nadir after mobilization chemotherapy (P=0.878) and similar amount of platelet transfusion (median 0 vs.1 unit,P=0.735) when compared with the GCSF alone arm (n = 20). On the day of leukapheresis, the median platelet count was 86 ×10^(9)/L (range 18-219) among patients who received rhTPO and 73 ×10^(9)/L (range 42-197) among those who received GCSF alone (P=0.982). After the use of rhTPO, the incidence of platelet count <75 ×10^(9)/L on the day of leukapheresis did not decrease significantly (30.0% vs. 50.0%,P=0.297).Platelet recovery after PBPC transfusion was more rapid in the rhTPO plus GCSF arm (median 8.0 days [95% confidence interval 2.9-13.1] to platelets ≥50 ×10^(9)/L vs. 11.0 days [95% confidence interval 8.6-13.4],P=0.011).The estimated total cost of the mobilization and reconstitution phases per patient was similar between the two treatmtent groups (P=0.362 andP=0.067,respectively).Conclusions:Our findings indicate that there was no significant clinical benefit of rhTPO use in facilitating mobilization of progenitor cells,but it may promote platelet recovery in the reconstitution phase after high-dose therapy.Trial registration:This trial has been registered in Clinicaltrials.gov as NCT03014102.